Founder of Meabco A/S in 2001 and Angel investor. Life long experience in commercial start ups.
Sergey holds a PhD in International Economy and has 17 years of experience in managing multinational research and development projects (nonclinical, clinical, cmc).
Fredrik holds a M.Sc. in International Business from Copenhagen Business School and have conducted studies in Advanced Corporate Finance at London Business School. Fredrik has 20 years of experience from senior positions within M&A, Strategy and Corporate Finance incl. 6 years as CFO at Lauritzen Fonden.
Henning ArboeAdministration & Project Manager
Henning has extensive practical experience in HR, and has worked as Manager for several international companies.
Andrey PanchenkoNonclinical Research
Andrey holds a degree of Medical Doctor from Pavlov Saint Petersburg State Medical University, PhD in pathophysiology and oncology.
More than 50 papers in medical journals in the field of pathology and oncology.
Tea Kirkegaard NielsenResearch & Development
PhD and M.Sc. Molecular Biology
Experienced Research And Development Scientist with a demonstrated history of working in the Research and Pharmaceutical industry.
Meabco Advisory board
Prof. Svend Aage EngelholmOncology and Radiation Oncology
Professor Svend Aage Engelholm, MD., D.MSci, University of Copenhagen.
Published more than 250 papers in peer-reviewed journals
Prof. Stig LarsenClinical Research & Development
Professor, DSc. at the Norwegian University of Life Science and has published more than 300 papers in international medical and clinical research methodological journals.
Prof. Henrik HarlingOncology
Associate Professor of Surgery, MD., D.MSci, University of Copenhagen. More than 110 papers in surgical and oncological journals with peer-review.
Meabco Board Members
Bent Østergaard has extensive management experience from a career of 50 years in international business. Bent Østergaard has held several top management positions such as CEO of Lauritzen Fonden and LF Investment ApS as well as CFO of J. Lauritzen A/S. He also has significant experience from board work among others from positions as Chairman of DFDS A/S, J. Lauritzen A/S and a number of other Danish and international companies.
Today Bent Østergaard focuses on board assignments and is chairman of Frederikshavn Maritime Erhvervspark A/S and Cantion A/S. In addition, Bent Østergaard is a board member of Desmi A/S, Jens og Margrethe With’s Fond, Durisol UK, Minervax ApS, Nanonord A/S and SmartVan A/S.
Bent Østergaard has been a member of the board of Meabco Holding A/S since 2011 and chairman since 2015.
Hans Carl, PhD, Secretary and former Chairman of Meabco, Chairman or board member of several companies and associations including chairman of an anti-cancer association. Regional coordinator of the French association on research of the side effects of radiation exposure. Former director in UNCTAD, the United Nations Conference on Trade and Development.
Tommy Thomsen is the CEO of Lauritzen Fonden (“LF”) and chairman of J. Lauritzen A/S. LF is the parent company of the shipping companies J. Lauritzen (wholly owned) and DFDS (42,5% holding), as well as the private limited company LF Investment ApS. LF Investment’s portfolio includes investments in companies in the offshore, ship owning, measuring equipment, biotechnology and real estate sectors.
Tommy Thomsen is also chairman of Den Danske Maritime Fond and C.W. Obel A/S. Tommy Thomsen is a board member of PSA International Pte Ltd, Chemical Transportation Group and Rederklubben. Tommy Thomsen is also on the advisory board of Canal de Panama and Portchain.
In addition to extensive management experience, Tommy Thomsen possesses in depth knowledge and global experience of business development, strategy and finance.
Philip Nyholm is a transactional / corporate lawyer and Managing Partner at DANDERS & MORE law firm. Philip Nyholm focuses on stock market law, company law, M&A as well as general commercial advice. Through a number of years, Philip has also been involved with several biotech companies and the challenges faced by this type of company.
Linda Sjöström is an experienced senior executive in the pharmaceutical industry and investment partner in the venture capital industry investing in and developing biotech companies with the aim of an IPO or sale to industrial partners. Linda has acted as chairmen and board member in numerous Boards of Directors in DK, Europe and the US. Linda is educated as Master of Science in Chemical Engineering.